Trial Profile
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SGN CD352A (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seagen
- 08 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 28 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.